Back to Journals » International Medical Case Reports Journal » Volume 10

Extraordinary and prolonged Erlotinib-induced clinical response in a patient with EGFR wild-type squamous lung cancer in third-line therapy: a case report

Authors Gambale E, Carella C, Amerio P, Buttitta F, Patea RL, Natoli C, De Tursi M

Received 17 February 2017

Accepted for publication 16 March 2017

Published 23 May 2017 Volume 2017:10 Pages 173—175

DOI https://doi.org/10.2147/IMCRJ.S134944

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Yusuke Okuma

Peer reviewer comments 2

Editor who approved publication: Professor Ronald Prineas


Elisabetta Gambale,1 Consiglia Carella,1 Paolo Amerio,2 Fiamma Buttitta,3 Rosa Lucia Patea,4 Clara Natoli,1 Michele De Tursi1

1Medical Oncology Unit, Department of Medical, Oral and Biotechnological Sciences, 2Department of Dermatology and Venereology, University G. d’Annunzio, Chieti, 3Department of Medicine and Aging Sciences, University of Chieti-Pescara, Chieti, 4Department of Radiologic Sciences, University of Chieti-Pescara, Chieti, Italy

Abstract: Several small molecules, epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), such as gefitinib, erlotinib and afatinib, have been demonstrated to significantly improve clinical outcomes in patients with advanced EGFR-mutated non-small cell lung cancer (NSCLC), but erlotinib activity in EGFR wild-type squamous carcinoma is still highly debated. Here, we describe a prolonged and unexpected clinical response to erlotinib in a male former heavy cigarette smoker with wild-type EGFR squamous-cell cancer.

Keywords: erlotinib, squamous NSCLC, EGFR wild type

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]